tbuckley/cabot-search huggingface dataset:
PTU-097 Nutritional Screening in Patients with Colorectal Cancer Prior to Elective Surgery: Is it Done Accurately and Does It Predict Outcome?
Authors: E Wesley, B Thompson, J Tham, N Smart, B Engel, I Daniels
Journal: Gut (2016)

<h3>Introduction</h3> Patients undergoing surgery for colorectal cancer (CRC) are at high risk of malnutrition, this is detrimental to their post-operative outcome. Nutritional screening is performed pre-operatively using the malnutrition universal screening tool (MUST) but the accuracy of completion and its ability to predict post-operative outcome is currently unknown. <h3>Aims</h3> To assess the frequency and accuracy in which MUST scoring is completed in the real world setting of a colorectal unit of busy teaching hospital To identify whether the pre-operative MUST score predicts poor outcome after CRC surgery in terms of increased risk of complications and length of hospital stay. <h3>Methods</h3> 136 consecutive patients undergoing elective surgery for CRC were prospectively independently MUST scored by 2 study investigators. Data was prospectively collected on the MUST score calculated by nursing staff as well as information on patient demographics, operative details and post-operative outcomes. <h3>Results</h3> 76 (56%) were male. The age range was 46–97, median 73, 75% of the patients were &gt;65. The BMI range was 14.6–43, median 26.1. 32% of the patients had right colon lesions, 21% left colon and 43% rectal. MUST scoring was almost universally completed by nursing staff (98.5%)but the accuracy was poor with significant differences in scores (p = 0.001). The weight loss component of the scoring was the source of error. 73% of the patients had a MUST score of 0, 19% had a score of 1 and 8% ≥ 2. 60% of patients had their surgery by the laparoscopic approach. 61.5% experienced no post-operative complications, 9.5% experienced significant complications (Clavien-Dindo 3 a-5). Hospital length of stay ranged from 0–43 days, median 6 days. MUST score was not able to predict the risk of post-operative outcome as defined by an increased risk of post-operative complications (p = 0.96) or increased length of hospital stay (p = 0.95). ASA status showed a trend towards significance for predicting post-operative complications (p = 0.06). <h3>Conclusion</h3> MUST screening is almost universally done however the accuracy is poor. There is a risk that patients who are at risk of malnutrition and may benefit from nutritional support are being overlooked. MUST screening alone did not predict an increased length of hospital stay or risk of post-operative complications. The prevalence of malnutrition as detected by MUST score was low. This is likely to be because a significant proportion of the patients were overweight or obese. An alternative screening tool such as the short nutritional assessment questionnaire (SNAQ) might be more suitable in this patient group. <h3>Disclosure of Interest</h3> None Declared
Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma
Authors: Takashi Ishida, Michinori Ogura, Kiyohiko Hatake, Masafumi Taniwaki, Kiyoshi Ando, Kensei Tobinai, Katsuya Fujimoto, Kazuhito Yamamoto, Toshihiro Miyamoto, Naokuni Uike, Mitsune Tanimoto, Kunihiro Tsukasaki, Kenichi Ishizawa, Junji Suzumiya, Hiroshi Inagaki, Kazuo Tamura, Shiro Akinaga, Masao Tomonaga, Ryuzo Ueda
Journal: Blood (2012)
Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member B (ANP32B), a Novel Caspase-3 Substrate, Exerts Anti-Apoptotic Effects on Acute Myeloid Leukemic Cells.
Authors: Yun Yu, Shao-Ming Shen, Li-Shun Wang, Qian Zhao, Guo-Qiang Chen
Journal: Blood (2008)
P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials
Authors: N. Reau, M.W Fried, H. Wedemeyer, C. Cooper, M. Diago, A. Craxi, S. Strasser, J.-F. Dufour, W. Xie, L. Larsen, E.O. Dumas, D. Bernstein
Journal: Journal of Hepatology (2015)
P1.16: Comparison of Peri-Operative Outcomes After Robotic-Assisted Video-Thoracoscopic Lobectomies Versus Segmentectomies
Authors: Maria F. Echavarria, Anna Cheng, Frank Velez, Emily Ng, Eric Toloza, Carla Moodie, Joseph Garrett, Jacques-Pierre Fontaine
Journal: Journal of Thoracic Oncology (2016)
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
Authors: Kirsten Bibbins-Domingo, David C. Grossman, Susan J. Curry, Karina W. Davidson, John W. Epling, Francisco A. R. García, Matthew W. Gillman, Alex R. Kemper, Alex H. Krist, Ann E. Kurth, C. Seth Landefeld, Michael L. LeFevre, Carol M. Mangione, William R. Phillips, Douglas K. Owens, Maureen G. Phipps, Michael P. Pignone
Journal: JAMA (2016)

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).
THU0158 Which Patient Characteristics Influence The Choice of Biological Therapy after First TNF Inhibitor Therapy in RA? A Nationwide Study of Channeling in Sweden 2010-2012:
Authors: T. Frisell, D. Di Giuseppe, S. Ernestam, H. Forsblad-d'Elia, L. Jacobsson, C. Turesson, R. van Vollenhoven, J. Askling
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The past decade has seen the introduction of many biological DMARDs (bDMARDs) for treating RA, but there is only limited evidence from comparative studies to guide the choice of therapy for specific patients. Whilst a TNF inhibitor (TNFi) is typically used as the first bDMARD, many patients will switch from this initial therapy. The choice of the next bDMARD is, however, largely a matter of patient and physician preference. Perceived or established differences between available bDMARDs may lead to non-random allocation of treatment, a quantification of which is essential for a correct assessment of comparative effectiveness and safety in observational studies. <h3>Objectives</h3> To describe baseline patient characteristics at initiation of different bDMARDs after a switch from a TNFi as first bDMARD <h3>Methods</h3> Patients with RA who initiated a second bDMARD in 2010–2012 within one year of discontinuing initial TNFi treatment were identified using the Swedish Rheumatology register (SRQ). Data on disease history, defined as ever diagnosed with relevant co-morbidities, were retrieved by linking to the nationwide and virtually complete Swedish Patient Register. <h3>Results</h3> The most common bDMARDs after initial TNFi therapy were rituximab and etancercept; the least common was infliximab. Across drugs, there were only modest differences in demographics and RA characteristics, and moderate differences in disease history. Those initiating a second TNFi were slightly younger, less often RF+, and had slightly lower DAS28 than those initiating a non-TNFi bDMARD. Initiators of rituximab had longest disease duration, highest proportion RF+ and with history of malignancy or COPD, while etanercept-initiators had the lowest proportion with history of malignancy. Those initiating a second TNFi had more often switched due to adverse events, though lack of effect was the most common reason for all drugs. <h3>Conclusions</h3> We observed some evidence for channeling regarding disease history, both by class and by drug within class. These differences were small compared to previously reported channeling to non-TNFi as first bDMARD, but should still be taken into account in observational studies of comparative effectiveness and safety of different biological therapies. <h3>Disclosure of Interest</h3> None declared
Normal body mass index with central obesity has increased risk of coronary artery calcification in Korean patients with chronic kidney disease
Authors: Mi Jung Lee, Jung Tak Park, Kyoung Sook Park, Young Eun Kwon, Seung Hyeok Han, Shin-Wook Kang, Kyu Hun Choi, Kook-Hwan Oh, Sue Kyung Park, Dong Wan Chae, Kyubeck Lee, Young-Hwan Hwang, Soo Wan Kim, Yeong Hoon Kim, Sun Woo Kang, Joongyub Lee, Curie Ahn, Tae-Hyun Yoo
Journal: Kidney International (2016)
AB0765 Identification of Neuropathic Pain Component in Patients of Various Age with Knee Osteoarthritis
Authors: V. Povoroznyuk, U. Pryimych
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoarthritis-induced pain is a result of nociceptor stimulation, associated with local tissue damage and inflammation. Resent data suggest the presence of neuropathic pain symptoms in patients with osteoarthritis. <h3>Objectives</h3> The aim of this study was to estimate the structure of pain syndrome, reveal the presence of neuropathic pain (NP) component, symptoms and signs of NP in patients suffering from knee osteoarthritis. <h3>Methods</h3> We9ve examined 44 patients with knee osteoarthritis of the II-III stages by the Kallgrene-Lawrence scale aged 47–85 years (average age 66,1±1,5 years). Patients were divided according to age into next groups: 47–60, 61–74, 75–85 years. To assess the NP component, we used screening scales painDETECT, LANSS, DN4 questionnaires. To assess intensity of pain, visual analogue scale (VAS) was used. Besides WOMAC and EuroQol-5D questionnaire were applied. For statistical analysis of results, ANOVA, correlation and regression analysis, chi square (χ<sup>2</sup>) were applied. <h3>Results</h3> 72,7% of patients with knee osteoarthritis examined by painDETECT were unlikely to have the NP component, 22,7% might possibly, 4,6% – probably. LANSS scale: 25% were probably to have NP. DN4 scale: 31,2% probably had NP. Moderate to significant correlations were found between intensity of pain by VAS data and Neuropathic Pain Scales (painDETECT, LANSS, DN4) data (p&lt;0,05). It was established than higher results of screening by painDETECT and DN4 positively correlate with a disturbance of physical function tested by WOMAC (p&lt;0,05). PainDETECT data have moderate to significant correlations with EuroQol-5D questionnaire (p&lt;0,01). Verbal descriptors as pins and needles, tingling, numbness and allodynia, pain from light touch which are revealed by 3 screening scales can significantly contribute to the likely neuropathic component in patients with knee osteoarthritis (p&lt;0,05). Burning pain (p&lt;0,01), pins and needles (p&lt;0,05) can be associated with a more severe pain in patients with knee osteoarthritis. <h3>Conclusions</h3> Thus, in patients with osteoarthritis the pain syndrome may reveal NP features. Identification of these would promote a targeted treatment strategy. <h3>Disclosure of Interest</h3> None declared
G-CSF Stem Cell Mobilization Is Protective Against Acute Graft-Versus-Host Disease (aGvHD) by Increasing Myeloid-Derived Suppressor Cell (MDSC) Frequencies
Authors: Cristiana Carniti, Antonio Vendramin, Silvia Gimondi, Anisa Bermema, Fabiana Riva, Jacopo Mariotti, Paolo Corradini
Journal: Blood (2012)
Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD
Authors: Niels Teich, Bernd Bokemeyer, Wolfgang Mohl, Jens Walldorf, Tony Bruns, Carsten Schmidt, Andreas Stallmach
Journal: Gut (2016)

In a recently published study of asymptomatic volunteers from a population-based study (n=3966) and healthy blood donors (n=1444), genetic polymorphisms that determine the fucosyltransferase-2 non-secretor status and the ABO blood type B were significantly associated with increased serum lipase activities.1 Furthermore, the study was the first one to identify the inherited Lewis and ABO blood group systems as relevant factors for the development of pancreatitis, that is, blood group B carriers displayed 1.69-fold odds of developing chronic pancreatitis.1 Little is known about the pathogenesis of azathioprine-induced acute pancreatitis (AIAP) in patients with inflammatory bowel diseases (IBDs). In a first prospective multicentre study on the incidence of AIAP in patients with thiopurine-naive IBD, we were able to identify smoking at the time of azathioprine induction as the strongest and dose-dependent risk factor.2 Stimulated by the findings of Weiss et al ,1 we have this time investigated whether patients with IBD who …
Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
Authors: Roger Lyons, James N. George, Francois Lefrere, Alan E. Lichtin, Michael D. Tarantino, Howard R. Terebelo, Jean-Francois Viallard, Reggie Kelly, Matthew Guo, Janet Nichol
Journal: Blood (2007)
AB0499 Bone Mineral Density in Postmenopausal Mexican Women with Systemic Lupus Erythematosus
Authors: P. Soto-Santillan, C. Mendoza-Pinto, S. Mendez-Martinez, L. Leon-Vazquez, I. Etchegaray-Morales, J.-C. Solis-Poblano, M.-A. Enriquez-Guerra, A. Montiel-Jarquin, A. Lopez-Colombo, M. Garcia-Carrasco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is accepted that patients with SLE exhibit an increased risk for low BMD and bone fractures; nevertheless, few studies have evaluated bone disorders in Latin American population. It is the first study that has evaluated frequency and correlations of low BMD in postmenopausal mestizo Mexican women with SLE <h3>Objectives</h3> To determine the frequency of osteoporosis and possible risk factor for low bone mineral density (BMD) in postmenopausal mestizo Latino American women with systemic lupus erythematosus (SLE) <h3>Methods</h3> A cross-sectional study was conducted among 100 postmenopausal patients with SLE. Patients were evaluated using a questionnaire about the follow variables: age at the time of the study, age at menopause, disease duration, disease activity, damage of the disease, cumulative corticosteroid dose, and history of fracture. Lumbar spine and hip measurements of BMD were performed by dual absorptiometry. Univariate and multivariate statistical analyses were used to assess relationship between risks factor and BMD. <h3>Results</h3> The mean age was 53.8±9.56 years and the mean SLE duration was 73.2±65 months. The mean BMD of the lumbar spine was 0.944±0.178 g/cm<sup>2</sup> and the hip was 0.915±0.135 g/cm<sup>2</sup>. Osteopenia was present in 63% and osteoporosis in 31%. In the univariate analysis, age at the time of the study and menopause duration were associated with low BMD at the hip while age at the time of the study, menopause duration and damage of the disease were associated with low BMD at the lumbar spine. In the multiple regression analysis, low BMD in lumbar spine and hip were associated only with age (B= -0.0004, P=0.017; B= -0.0006, P= &lt;0.05). <h3>Conclusions</h3> Osteopenia was found in 63% and osteoporosis in 31%. Risk factor for low BMD in both total hip and lumbar spine in postmenopausal SLE women was age. <h3>Disclosure of Interest</h3> None declared
Hemophagocytic Syndrome (HPS) Post Reduced Intensity Cord Blood Transplantation (RI-CBT) in Adult Patients with Hematological Diseases.
Authors: Kazuhiro Masuoka, Shigesaburo Miyakoshi, Shinsuke Takagi, Daisuke Kato, Eiji Kusumi, Tomoko Matsumura, Koichiro Yuji, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi
Journal: Blood (2005)
Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.
Authors: Jonathan D. Schoenfeld, Danielle Nina Margalit, Irene M. Shui, Julie L. Kasperzyk, Howard D. Sesso, Neil E. Martin, Paul Linh Nguyen, Philip W. Kantoff, Jennifer R. Rider, Lorelei A. Mucci
Journal: Journal of Clinical Oncology (2013)

2 Background: Prostate-directed RT results in local inflammation that may contribute to short-term toxicity and subsequently effects on long-term quality of life (QOL). We sought to explore the hypothesis that SNPs in inflammation-related genes may influence QOL sequelae following definitive prostate cancer RT. Methods: We studied Caucasian participants in the prospective US Physicians’ Health Study diagnosed and treated with RT for non-metastatic prostate cancer between 1982 and 2006. Forty-three SNPs in 10 inflammation-related genes were genotyped and analyzed using the additive model. Men were followed for cancer-specific QOL outcomes with regularly administered questionnaires. We dichotomized the maximum score for four parameters (decreased urinary stream, increased urinary frequency, rectal urgency and impotence) relevant to RT reported at least one year following RT and analyzed associations between scores and SNPs using Fisher’s exact tests and logistic regression. Results: We identified 264 men with QOL data who previously provided blood for genotype analysis and received RT at a median age of 72 years (IQR 68 – 76 years). Features at diagnosis included: 67% PSA&lt;10, 61% Gleason&lt;7, 95% T1/T2 disease and 71% Charlson co-morbidity index 0-1. QOL questions were completed a median of 6 years following RT. Without adjusting for multiple testing, 13 SNPs had nominally significant associations (p &lt; 0.05) with QOL parameters; 7 remained significant after adjusting for age, features at diagnosis, and use of brachytherapy (Table). Conclusions: We identify candidate SNPs in inflammation-related genes that can be further explored in regards to their associations with long-term effects of prostate-directed RT. [Table: see text]
Abstract 2765: Evaluation of family history of cancer in first-degree relatives and increased cancer risk: A multinational study
Authors: Laxmi Modali, Teresa A. Lehman, Ramakrishna Modali, Luke D. Ratnasinghe
Journal: Cancer Research (2015)

Abstract Family history of cancer is a known risk factor for several of the more prevalent cancer types. However, familial aggregation of cancer may not follow the genetic linkage pattern seen with most inherited cancer syndromes. In these instances, clustering may be due to unknown hereditary genetic mutations or to an aggregation of environmental risk factors and such clustering may still confer a significant risk. We assessed the association between family history of cancer in first-degree relatives and cancer risk among 9,122 cancer cases and 76,537 controls in a multinational study. Analyses also included evaluation of breast, colon and prostate cancer risk associated with family history of these respective cancer types. Cases were verified by physician diagnosis and all study participants were administered an in-depth survey to ascertain various demographic and lifestyle factors as well as a complete family history of cancer among first-degree relatives. Multivariable logistic regression was used to assess the association between family history of cancer and cancer risk. Among all subjects, the odds ratio (OR) for individuals with a family history of cancer was 1.79 [95% confidence interval = 1.7-1.9] after adjusting for age, gender, BMI, smoking pack years and ethnicity. Additionally, a greater cancer risk was associated with increasing number of first-degree relatives with a history of cancer. Ethnic groups studied included Caucasian-Americans, African-Americans, Hispanic/Latinas and Caucasian-Polish. All ethnic groups showed a significant association between family history of cancer and cancer risk with the highest adjusted OR of 2.65 [95% confidence interval = 2.0-3.6] among the Hispanic/Latina group. Further analyses indicated that family history of colon, breast and prostate cancer was significantly associated with an increased risk of these respective cancer types across studied ethnic groups. In particular, the adjusted ORs for breast, colon and prostate cancer risk in the Caucasian-Polish group were at least double the overall adjusted ORs for each cancer type. Our study shows that family history of cancer is a significant predictor of cancer risk especially among certain ethnic groups. In addition, family history of cancer can represent both a genetic predisposition and/or environmental exposure and risk associated with familial clustering of cancer. Citation Format: Laxmi Modali, Teresa A. Lehman, Ramakrishna Modali, Luke D. Ratnasinghe. Evaluation of family history of cancer in first-degree relatives and increased cancer risk: A multinational study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2765. doi:10.1158/1538-7445.AM2015-2765